Janssens R, Lang T, Vallejo A, Galinsky J, Plate A, Morgan K, Cabezudo E, Silvennoinen R, Coriu D, Badelita S, Irimia R, Anttonen M, Manninen RL, Schoefs E, Vandebroek M, Vanhellemont A, Delforge M, Stevens H, Simoens S, Huys I. Patient preferences for multiple myeloma treatments: a multinational qualitative study. Front Med (Lausanne). 2021 Jul 6;8:686165. doi: 10.3389/fmed.2021.686165
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L, Rosen R. Help-seeking behavior of women with self-reported distressing sexual problems. J Womens Health. 2009 Apr 1;18(4):461-8.
Williams VSL, Jones G, Mauskopf J, Spalding J, Duchane J. Uterine fibroids: a review of health-related quality of life assessment. J Womens Health. 2006 Sep 7;15(7):818-29.
Johannes CB, Avis NE. The short-term health consequences of hysterectomy. Poster presented at the 4th Annual Congress on Women's Health; 1996. Washington, DC. [abstract] J Womens Health. 1996; 5:278.